Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2193-2201

  Merchant, Joseph ^a   Tutsch, Kendra ^a   Dresen, Amy ^a   Arzoomanian, Rhoda ^a   Alberti, Dona ^a   Feierabend, Chris ^a   Binger, Kim ^a   Marnoccha, Rebecca ^a   Thomas, James ^a   Cleary, Jim ^a   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,11 DICHLORO 6 (2 DIETHYLAMINOETHYL) 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 (4 O METHYLGLUCOSIDE); REBECCAMYCIN; REBECCAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ACCESS; VEIN INJURY; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; NEUTROPENIA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, AMINOGLYCOSIDE; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGE; NEOPLASMS; NEUTROPENIA; SUPPORT, U.S. GOV'T, P.H.S.; THROMBOCYTOPENIA; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; HUMANS; MIDDLE AGED;

EID: 0035992341     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Enhanced binding to DNA and topoisomerase I inhibition by an analogue of the antitumor antibiotic rebeccamycin containing an amino sugar residue
2. Production and biological activity of rebeccamycin, a novel antitumor agent
3. Recent developments of rebeccamycin analogues as topoisomerase I inhibitors and antitumor agents
4. A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I
5. Water soluble derivatives of rebeccamycin
6. Structureactivity relationships in a series of substituted indolecarbazoles: Topoisomerase I and protein kinase C inhibition and antiumoral and antimicrobial properties
7. Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle
8. In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors
9. Rowinsky pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties
10. Phase I clinical and pharmacokinetic study of rebeccamycin analogue NSC 655649 given daily for five consecutive days
11. DNA topoisomerase I and II as targets for rational design of new anticancer drugs